Literature DB >> 19470616

Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience.

S Scigliano1, R Lebtahi, F Maire, J L Stievenart, R Kianmanesh, A Sauvanet, M P Vullierme, A Couvelard, J Belghiti, P Ruszniewski, D Le Guludec.   

Abstract

Liver metastases are common in gastroenteropancreatic neuroendocrine tumors and significantly impair survival. Hepatic resection is the only potential curative treatment. The records of 41 consecutive patients undergoing exhaustive resection of liver-only endocrine metastases and followed between 1992 and 2006 were reviewed. Patient's outcome and diagnostic accuracy of somatostatin receptor scintigraphy (SRS) and morphological imaging (MI) for detection of recurrences during post-operative follow-up were assessed. All identified primary had been resected. MI studies including abdominal computed tomography (CT) and/or liver magnetic resonance imaging and thoracic CT if indicated were performed every 6 months; SRS timing was decided by referring clinician. Tumor recurrences were confirmed by pathology or subsequent imaging studies. The results of 136 MI and SRS examinations performed within a 30-day interval from each other were retrospectively compared. Median post-operative follow-up was 51 months (7-165). Recurrences developed in 32 patients (78%), mainly in the liver (n=24) after a median of 19 months (2-79). Five-year overall and disease-free survival rates were 79 and 3% respectively. For recurrence detection, sensitivity, specificity, and accuracy were 89, 94, and 91% for SRS, 68, 91, and 74% for MI respectively. In 11 out of 32 patients (34%), abdominal or extra-abdominal metastases were detected 15.5 months earlier by SRS than MI. In conclusion, despite exhaustive liver surgery for endocrine metastases, hepatic or extra-hepatic recurrences are frequent and develop early. SRS is highly accurate for the detection of recurrences during post-operative follow-up and permitted early diagnosis in one third of patients; therapeutic implications of this early diagnosis remain to be determined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19470616     DOI: 10.1677/ERC-08-0247

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  23 in total

Review 1.  Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor.

Authors:  Sayee Sundar Alagusundaramoorthy; Roberto Gedaly
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 2.  Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.

Authors:  Tetsuhide Ito; Susumu Hijioka; Toshihiko Masui; Atsuko Kasajima; Yuji Nakamoto; Noritoshi Kobayashi; Izumi Komoto; Masayuki Hijioka; Lingaku Lee; Hisato Igarashi; Robert Thomas Jensen; Masayuki Imamura
Journal:  J Gastroenterol       Date:  2016-08-18       Impact factor: 7.527

Review 3.  The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons.

Authors:  Carlo Sposito; Michele Droz Dit Busset; Davide Citterio; Marco Bongini; Vincenzo Mazzaferro
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

4.  Neuroendocrine liver metastases: contributions of endoscopy and surgery to primary tumor search.

Authors:  Herwig Cerwenka
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

Review 5.  Multimodal management of neuroendocrine liver metastases.

Authors:  Andrea Frilling; Georgios C Sotiropoulos; Jun Li; Oskar Kornasiewicz; Ursula Plöckinger
Journal:  HPB (Oxford)       Date:  2010-08       Impact factor: 3.647

Review 6.  Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies.

Authors:  Skye C Mayo; Joseph M Herman; David Cosgrove; Nik Bhagat; Ihab Kamel; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2012-10-11       Impact factor: 6.113

Review 7.  Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1.

Authors:  Kazuhiro Hanazaki; Akihiro Sakurai; Masaya Munekage; Kengo Ichikawa; Tsutomu Namikawa; Takehiro Okabayashi; Masayuki Imamura
Journal:  Surg Today       Date:  2012-10-19       Impact factor: 2.549

Review 8.  Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors.

Authors:  Miral Sadaria Grandhi; Kelly J Lafaro; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-09-04       Impact factor: 3.452

9.  Surgical treatment of liver metastases in neuroendocrine neoplasms.

Authors:  Palepu Jagannath; Deepak Chhabra; Shailesh Shrikhande; Rajiv Shah
Journal:  Int J Hepatol       Date:  2012-01-26

Review 10.  Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review.

Authors:  Sven-Petter Haugvik; Knut Jørgen Labori; Bjørn Edwin; Øystein Mathisen; Ivar Prydz Gladhaug
Journal:  ScientificWorldJournal       Date:  2012-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.